Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
Rhea-AI Summary
Tevogen Bio CEO Dr. Ryan Saadi will join a key panel discussion at BioNJ's Fifteenth Annual Bio Partnering Conference on May 13, 2025. The panel, "Paths to Liquidity: Strategies for Adapting to a Volatile Market," will feature experts from J.P. Morgan, RSM, and Cantor Fitzgerald.
The conference, hosted at The Liberty Science Center in Jersey City, NJ, aims to connect investors, business development professionals, and industry executives to boost strategic partnerships and funding opportunities. The event includes:
- One-on-one partnering sessions
- Company pitch presentations
- Industry Connections Desk
- Exhibits and networking opportunities
- Plenary discussions
Dr. Saadi emphasized the critical timing of addressing market volatility and its impact on patient outcomes, aligning with Tevogen's mission to improve access to affordable lifesaving treatments.
Positive
- CEO participation in high-profile panel with experts from major financial institutions (J.P. Morgan, RSM, Cantor Fitzgerald) increases company visibility
- Strategic networking opportunity with investors and BD professionals could lead to potential partnerships
Negative
- None.
WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today reminds that CEO Dr. Ryan Saadi MD, MPH will participate in BioNJ’s Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald.
The conference, held on May 13, 2025, at The Liberty Science Center in Jersey City, NJ, historically brings together investors, BD professionals, academic collaborators, innovators and biopharmaceutical industry executives to foster strategic partnerships, drive funding, and accelerate collaboration, with the ultimate goal of advancing medical innovation and transforming the future of healthcare.
“I look forward to joining in the upcoming panel discussion hosted by BioNJ,” said Dr. Saadi. “This is a critical moment for the biotechnology industry to address market volatility and its potential impact on patient outcomes. The topic is closely aligned with Tevogen Bio’s mission to advance accessibility and affordability to lifesaving treatments.”
“The conference’s action-packed agenda, featuring 1:1 partnering sessions, company pitch presentations, the Industry Connections Desk, exhibits, extensive networking opportunities and engaging plenary discussions, was thoughtfully designed to provide entrepreneurs with a dynamic environment geared toward growth and collaboration,” said BioNJ President and CEO Debbie Hart. “With that in mind, we’re thrilled to welcome Dr. Saadi and his fellow panelists to share their invaluable insights during “Paths to Liquidity: Strategies for Adapting to a Volatile Market”. Attendees are certain to walk away with meaningful, actionable takeaways.”
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
When and where is BioNJ's 15th Annual Bio Partnering Conference featuring Tevogen's CEO?
What is the focus of Tevogen (TVGNW) panel discussion at BioNJ 2025 conference?
Who are the key speakers joining Tevogen CEO at BioNJ's 2025 biotech panel?
What networking opportunities does BioNJ 2025 conference offer biotech investors?
How does the BioNJ 2025 conference align with Tevogen's business goals?
